BCL2 and acute myeloid leukemia: In addition to cell surface markers, the expression levels of the GAS6/AXL axis in cells have been shown to reflect primary resistance to venetoclax in AML cells and can be used as a marker to predict response to therapy, as well as the potential to indicate the need for combination therapy with AXL/BCL-2 inhibitors (101).